Proctitis – Drugs In Development, 2024
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Proctitis – Drugs In Development, 2024 report and make more profitable business decisions.
Proctitis is an inflammation in the lining of rectum. It can be chronic or acute. Causes of proctitis include IBD, sexually transmitted and gastrointestinal infections, radiation therapy, antibiotics, and NSAIDs. Some of the symptoms include anorectal pain; blood, mucus, or pus in the feces; swelling in the rectum; tenesmus (continuous feeling of bowel movement); dyschezia (painful bowel movements); and diarrhea or constipation. It can be diagnosed with the help of digital rectal examination, anoscopy, proctoscopy, flexible sigmoidoscopy, and blood test or culture tests for identifying infections. Treatment options vary depending on the cause. Antibiotics or antivirals can be used in case of infections, immunosuppressants for autoimmune related proctitis, and discontinuing use of a causative agent.
The Proctitis drugs in development market research report provide comprehensive information on the therapeutics under development for Proctitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Proctitis and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
Quick View – Proctitis | Key Targets |
|
|
Key Mechanisms of Action |
|
||
Key Routes of Administration |
|
||
Key Molecule Types |
|
||
Major Companies |
|
Scope
- Therapeutics in Development: Covering 5 molecules, with 5 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Proctitis therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Proctitis pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Proctitis treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Alfasigma SpABioCurity Pharmaceuticals Inc
First Wave BioPharma Inc
Shanghai Pharmaceuticals Holding Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Proctitis reports![](https://www.globaldata.com/store/wp-content/uploads/sites/2/blue_1bg2.webp)
![](https://www.globaldata.com/store/wp-content/uploads/sites/2/blue_1bg2.webp)
![](https://www.globaldata.com/store/wp-content/uploads/sites/2/blue_1bg2.webp)